NEI Podcast

Dr. Robyn Thom, Assistant Professor of Psychiatry at Harvard and clinician-researcher in autism care. She talks about how autism is diagnosed, core social and behavioral differences, and common co-occurring conditions like anxiety, ADHD, sleep problems, and agitation. Practical approaches for evaluating agitation, therapy and medication options, and research on syndromes like Williams are also discussed.

Robert O. Cotes, Professor of Psychiatry at Emory and leader of Project ARROW, specializes in early psychosis care. He discusses why the first episode is a critical window, the effects of untreated duration, and varied recovery paths. Conversations cover engaging young people and families, coordinated specialty care principles, measurement-based tracking, and innovations like digital biomarkers and precision approaches.

Dr. Lisa Harding, a Yale-affiliated psychiatrist specializing in interventional treatments for treatment-resistant depression. She contrasts IV ketamine and intranasal esketamine. Short, practical talks cover patient selection, monitoring and safety, access and cost, clinic operations, and risks of unsupervised at-home use.

Timothy Wilens, a Harvard psychiatrist and expert in ADHD and addiction medicine, cuts through myths about ADHD medications. He discusses why stigma persists, differences between stimulants and nonstimulants, diversion and misuse patterns, safety concerns, and how clinicians can counter misinformation. Multiple short, focused takes make complex evidence easy to follow.

Jonathan Meyer, psychopharmacology expert and UC San Diego professor, breaks down common myths about antipsychotic treatments. He covers how these drugs work, clarifies risks like brain damage and personality blunting, and discusses clozapine, long-acting injectables, dosing strategies, and use in mood disorders. Practical communication and individualized care are emphasized throughout.

Join Dr. Jeffrey Strawn, a leading expert in psychiatry and pharmacology, as he busts common myths surrounding antidepressants. He and Dr. Andy Cutler delve into the efficacy of these medications compared to placebos and clarify the risk of suicidality. They discuss when to initiate treatment, the importance of balancing medication with therapy, and how to effectively communicate side effects to patients. Strawn also tackles the misconception of antidepressants altering personality, emphasizing their role in symptom relief. A must-listen for anyone curious about mental health treatment!

Dr. Carla Sharp, a distinguished clinical psychologist from the University of Houston, dives deep into borderline personality disorder (BPD) with Dr. Andy Cutler. They dissect the challenges in diagnosing BPD and explore the latest APA guidelines. Carla highlights how framing BPD as a treatable condition can reduce stigma. The conversation spans the importance of therapy approaches, such as DBT and mentalization-based therapy, as well as the impact of genetics and trauma on BPD. Listeners gain valuable insights into effective treatment strategies and the necessity of early intervention.

Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry. Roger McIntyre, MD, FRCPC, is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. Resources Thanarajah ES et al. Soft drink consumption and depression mediated by gut microbiome alterations. JAMA Psychiatry 2025;82(11):1095–1102. doi:10.1001/jamapsychiatry.2025.2579 Durgam S et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry 2025;86(4):25m15848. doi: 10.4088/JCP.25m15848 Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789 Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025;645:712–21. doi: 10.1038/s41586-025-09335-x Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter

Stephen Stahl, a renowned psychiatrist and psychopharmacology expert, joins Roger McIntyre, a clinical researcher in mood disorders, to tackle the complexities of depression. They explore how to recognize and manage major depressive episodes with mixed features and the implications of DSM-5 specifiers on treatment. Highlights include discussions on the urgent need for updated guidelines, the efficacy of atypical antipsychotics, and the importance of individualized care to bridge the gap between evidence and practice in mental health treatment.

In this CME episode, Dr. Andy Cutler and Dr. Christoph Correll discuss the complexities of managing bipolar disorder, with a focus on recognizing and treating mixed states. They address overlapping manic and depressive symptoms, comorbidities, and the importance of shared decision-making, family involvement, and patient education. The conversation also explores strategies to improve adherence, the impact of substance use, and the value of a collaborative, individualized approach to long-term stability and recovery. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e269-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter